

**Comparison of clinical remission and survival between CLAG and FLAG
induction chemotherapy in patients with refractory or relapsed acute myeloid
leukemia: a prospective cohort study**

Running title: CLAG versus FLAG in treating R/R AML patients

Ying Bao¹, Juan Zhao², Zhang-Zhi Li^{3*}

¹Department of Hematology, Xiangyang NO. 1 People's Hospital, Affiliated to Hubei University of Medicine, Xiangyang, China;

²Department of Hematology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;

³Department of Hematology, Taihe Hospital Affiliated to Hubei University of Medicine, Shiyan, China.

Ying Bao and Juan Zhao contributed equally to this work.


***Correspondence:** Zhangzhi Li,

Department of Hematology, Taihe Hospital Affiliated to Hubei University of Medicine, 32 Renmin South Road, Shiyan 442099, China.

Tel: +86-719-8801443;

Fax: +86-719-8801443;

Email: lizhangzhi07@outlook.com



Supplemental Figure S1 Accumulating OS between FLAG and FLAG treatments in subgroups divided by baseline characteristics (Data with p value ≥ 0.1). No difference of OS between FLAG and FLAG in these subgroups was discovered (A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S). Comparison of OS between groups was determined by K-M curves and log-rank test. $p < 0.05$ was considered significant.